SecBot SecBot

LXRX

LEXICON PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001062822 Biotech & Drug Discovery
$1.75 −0.04 (−2.23%)
Nov 16 4:00 PM ET · prev $1.79
Market cap
$810.3M
Small cap
Consensus
Buy
75% Buy or better · 12 analysts
Median target
$4.70
+169% · range $1.69–8.00
1 year
+19.9%
from $1.46 · Nov 17
30 days
+12.9%
from $1.55
52-week range
$1.14–2.64
−34% from high · low Jan 2
Avg volume 20D
2.16M
shares / day
Short interest
25.88M
≈5.8% of shares · −3.1%
Days to cover
14.0
at average volume
Insider net
+$200.0K
2 buyers · 0 sellers · since Feb 23
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $200.0K at an average $1.51. No open-market sales. Price is 16% above their cost.

  • InstitutionsBULLISH

    Q3 2026: 19 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    9 of 12 rate it Buy or better. Median target $4.70 (+169%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.036 → −$0.054 over 90 days.

  • Short sellersSTEADY

    Short interest −3.1% to 25.88M shares. 14.0 days to cover, ≈5.8% of shares.

  • TrendRANGE

    1% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCADD66,743,390$125.1M
STATE STREET CORPADD7,467,459$14.0M
UBS Group AGDOUBLED1,826,437$3.4M
Squarepoint Ops LLCDOUBLED501,186$939.7K
MORGAN STANLEYADD201,536$377.9K
BARCLAYS PLCNEAR_EXIT93,199$174.7K
Quadrature Capital LtdDOUBLED79,595$149.2K
GROUP ONE TRADING LLCTRIM61,262$114.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 75% rate it Buy or better
Strong Buy3Buy6Hold3Sell0Strong Sell0
12-month targets · 6 analysts

Price is inside the target range. Median implies +169%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Citigroup
MAINTAIN
MAINTAINBuy
Sep 28, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$200.0K
bought · 2 insiders
$0
sold · 0 insiders
+15.6%
vs their $1.51 cost
DateInsiderTypeValue
Nov 6, 2026
Exton Michael
Chief Executive Officer
Nov 6, 2026
BUY$50.0K
Jun 3, 2026
DEBBANE RAYMOND
Director
Jun 3, 2026
EXERCISE89,312 sh
Jun 3, 2026
BARKER SAM L
Director
Jun 3, 2026
EXERCISE89,312 sh
Jun 3, 2026
Amouyal Philippe
Director
Jun 3, 2026
EXERCISE89,312 sh
Jun 3, 2026
Cheung Ivan
Director
Jun 3, 2026
EXERCISE89,312 sh
Jun 3, 2026
Sullivan Diane E.
Director
Jun 3, 2026
EXERCISE89,312 sh
Jun 3, 2026
SOBECKI CHRISTOPHER J
Director
Jun 3, 2026
EXERCISE89,312 sh
Jun 3, 2026
Swain Judith L
Director
Jun 3, 2026
EXERCISE89,312 sh

Earnings setup

Estimates
−$0.05
EPS estimate, this quarter
−50%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.05-$0.06–-$0.03-50.3%$4.3M
Next Q-$0.06-$0.06–-$0.06-20.0%$603.3K
Current FY-$0.16-$0.17–-$0.14+4.5%$37.4M
Next FY-$0.21-$0.27–-$0.11-11.7%$17.9M

Short side

FINRA· Oct 30, 2026
25,877,882
shares short
-3.1%
vs prior settlement
14.0
days to cover
≈5.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 11, 2026 Other
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
THE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
Nov 6, 2026 Insider
Exton Michael bought 30,064 shares
Chief Executive Officer @ $1.66 ($50.0K)
Nov 5, 2026 SEC
Fidelity (FMR LLC) filed an amended Schedule 13G reporting beneficial ownership of 66,743,389.66 shares of Lexicon…
SC 13G/A · Impact 2/10
Nov 5, 2026 SEC
Lexicon reported Q3 2026 total revenue of $11.3M, down from $14.2M a year ago, driven by lower licensing/milestone…
8-K · Impact 4/10
Nov 5, 2026 SEC
Lexicon reported Q3 2026 net loss of $0.03 per share, narrower than the consensus estimate of -$0.05, on total revenue…
PRESS-RELEASE · Impact 4/10
Sep 30, 2026 Inst.
FMR LLC · ADD
66,743,390 shares ($125.1M)
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
7,467,459 shares ($14.0M)
Jun 3, 2026 Insider
DEBBANE RAYMOND acquired via exercise 89,312 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

13 filings · 3 press releases · 1 bullish · 3 bearish · 9 neutral
All LXRX filing & press-release reports (16)